Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections

Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF), whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to report initial results of brolucizumab intravitreal injections (IVI) on type 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Gigon, Anthony, Vadalà, Maria, Bonfiglio, Vincenza M. E., Reibaldi, Michele, Eandi, Chiara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506440/
https://www.ncbi.nlm.nih.gov/pubmed/36143855
http://dx.doi.org/10.3390/medicina58091180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506440/
https://www.ncbi.nlm.nih.gov/pubmed/36143855
http://dx.doi.org/10.3390/medicina58091180

Ejemplares similares